City

Birmingham (1)

Boston (1)

Chapel Hill (1)

Chicago (1)

Guangzhou (1)

New York (1)

San Francisco (1)

Shanghai (1)

Condition

Advanced Breast Cancer (2)

Breast Cancer (1)

Breast Neoplasm (1)

HER2-negative Breast Cancer (1)

Hormone Receptor Positive Tumor (1)

Metastatic Breast Cancer (1)

Metastatic Triple Negative Breast Cancer (1)

Overall Status

Recruiting (2)

Not yet recruiting (1)

Terminated (1)

Phase

phase 2 (2)

n/a (1)

phase 3 (1)

Sponsor

Fudan University (1)

Memorial Sloan Kettering Cancer Center (1)

Sun Yat-sen University (1)

Wenjin Yin (1)

Collaborator

Astellas Pharma US, Inc. (1)

Breast Cancer Research Foundation (1)

Corcept Therapeutics (1)

Study Documents

Intervention Type

drug (4)

Funder Type

Other (4)

Study Type

Interventional (4)

tpc

Showing 1 - 4 of 4

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

LAST UPDATED

Advanced Breast Cancer Trial (XC, TPC)

Not yet recruiting

Advanced Breast Cancer

(no location specified)

May 16, 2023

Breast Tumor, Breast Cancer, Hormone Receptor Positive Tumor Trial in Shanghai (PIK3CA inhibitor, AKT inhibitor, Carrelizumab)

Recruiting

Breast Neoplasm
+4 more

PIK3CA inhibitor
+12 more

Shanghai, Shanghai, China

Breast cancer institute of Fudan University Cancer Hospital

Jan 2, 2023

Metastatic Breast Cancer Trial in United States (Enzalutamide, Mifepristone, TPC)

Recruiting

Metastatic Breast Cancer

Enzalutamide
+2 more

Birmingham, Alabama
+5 more

Oct 19, 2023

Metastatic Triple Negative Breast Cancer Trial in Guangzhou (TPC, Bicalutamide 150 mg)

Terminated

Metastatic Triple Negative Breast Cancer

TPC
Bicalutamide 150 mg

Guangzhou, Guangdong, China
+1 more

Jan 26, 2021